Overall survival is no better for patients diagnosed with NMIBC who progress directly to metastasis.

ImmunityBio’s IBRX QUILT-2.005 trial tops enrollment forecasts; BLA filing targeted by year-end after positive ANKTIVA+BCG ...

The extent of the bladder cancer — how far it has spread — matters. Your care team needs to know if your cancer sits on or in the first lining of your bladder (non-muscle invasive), if it goes into ...

ImmunityBio, Inc. (NASDAQ:IBRX) is one of the best penny stocks to buy for 2026. On December 16, ImmunityBio, Inc.

Theralase Technologies (USOTC:TLTFF) signed a clinical development agreement with Ferring Pharmaceuticals, a top name in ...

Senior male patient in hospital gown seen through CAT scan machine. Male patient at clinic for MRI scan. The 2023 guideline on managing muscle-invasive bladder cancer offers evidence-based ...

Approval of ANKTIVA was granted for BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC) with carcinoma in situ, with ...

The collaborative clinical study will evaluate ADSTILADRIN® (nadofaragene firadenovec-vncg) in combination with the ...

Most people with bladder cancer begin treatment by having surgery to remove their cancer. If bladder cancer has spread beyond your bladder, you might have chemotherapy first. This can help treat ...

There’s nothing that spoils your fun faster than leaving home and having bladder spasms strike immediately after. Racing to the nearest bathroom while worrying about the risk of a potential bladder ...